IL6 and COVID-19: Finally, given the global crisis due to SARS-CoV-2 infection, causing the disease COVID-19 that is associated with heightened cytokine release including IL-6 and hyperinflammation,82 this SLR aimed to summarise the best available evidence on the use of agents selectively targeting IL-6 axis for the management of SARS-CoV-2 infection.